Beyond Meat Shares Plummet Amid Financial Reporting Delay and Asset Write-Down Warning

Beyond Meat jolted investors Monday with a staggering 16% single-day decline after the company postponed its third-quarter earnings release and signaled substantial asset impairment charges. The plant-based protein producer's stock collapsed to $1.39 per share, marking another devastating blow for the already struggling enterprise.

The company's decision to reschedule its quarterly financial disclosure from November 4 to November 11 triggered immediate market concern. Management acknowledged that anticipated asset write-downs would be "material" but stated they're "not yet able to reasonably estimate the amount." This vague wording regarding the company's inability to quantify the financial damage amplified investor anxiety.

Accelerating Financial Decline

Preliminary third-quarter figures reveal the accelerating pace of Beyond Meat's deterioration. Revenue dropped 14% to just $70 million, building on the 19.6% decline recorded in the previous quarter and indicating worsening business momentum.

The geographic breakdown shows particularly troubling trends:
- U.S. retail sales plummeted 27% year-over-year
- International foodservice revenue declined 26%
- Gross margins contracted sharply to a meager 10-11%

The company's operational losses continue to mount. For the first half of 2025, Beyond Meat recorded an adjusted EBITDA loss of $64.5 million against revenue of just $143.7 million, highlighting severe profitability challenges.

Should investors sell immediately? Or is it worth buying Beyond Meat?

Regulatory Scrutiny and Analyst Pessimism

The dramatic stock plunge attracted regulatory attention, with several law firms announcing investigations into potential securities law violations. The probes focus on whether Beyond Meat may have artificially inflated the valuation of certain assets on its balance sheet.

Market experts remain overwhelmingly bearish. Of 13 covering analysts, nine currently recommend selling the stock. JP Morgan has identified Beyond Meat as a top short candidate in its research. While the average price target of $2.23 sits approximately 60% above current trading levels, the most pessimistic forecast envisions the stock falling to just $0.80.

Survival Strategy Under Pressure

Beyond Meat confronts challenges across multiple fronts. Shifting consumer preferences, competition from weight-loss medications, and health-related misinformation about its products continue to pressure demand. Operational hurdles include suspended operations in China and workforce reductions.

In response to the crisis, the company has brought aboard turnaround specialist John Boken as part of emergency measures. Management aims to achieve positive EBITDA by the second half of 2026—an ambitious target given the current downward trajectory.

With shares hovering near multi-year lows, the delayed quarterly report scheduled for November 11 will provide critical insight into the true depth of Beyond Meat's financial predicament.